For sales

📢Highlights from the Week of 21 July , 2025 – 28 July, 2025  in the world of pharma and healthcare! 🗞️👀

VYUHPHARMA Highlights from the Week of July 21-28, 2025 APRECIA THE 30P PHARMACEU FDA approved label expansion of SPRITAM to include its administration via NG and G-Tubes for patients unable to swallow pills AVIDITY BIOSCIENCES Avidity's Del-Zota received FDA Breakthrough Therapy Designation for the treatment of Duchenne muscular dystrophy patients with exon 44 skipping mutations ATHINGS Pierre Fabre FDA grants priority review to Pierre Fabre's application for tabelecleucel as a treatment for EBV+ PTLD (Spritam, FDA, approval) (DelZota, Breakthrough Therapy) (FDA, Priority Review) Pg 1/7 All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.